Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today provided an update on its clinical development plans for CPP-109, its product candidate based on vigabatrin for the potential treatment of cocaine and methamphetamine addiction. The Company reported that it has decided to reduce the number of patients in its contemplated U.S. Phase II clinical trial evaluating the use of CPP-109 in treating cocaine addiction from 375 patients to between 100 and 150 patients. [click link for full article]
More...